TTP273
Type 2 Diabetes
Phase IICompleted
Key Facts
About Huadong Medicine (HD Medicine)
Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |
| V-Go | MannKind | Approved |
| Type 2 Diabetes Management | iWel | Development |
| Band-assisted Duodenal Mucosal Resurfacing (DMR) | Endolastic | Pre-clinical |
| REMD-477 (Volagidemab) | REMD Biotherapeutics | Phase 2 (completed) |